Search alternatives:
linear decrease » linear increase (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
i large » ai large (Expand Search), _ large (Expand Search), b large (Expand Search)
a large » _ large (Expand Search)
linear decrease » linear increase (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
i large » ai large (Expand Search), _ large (Expand Search), b large (Expand Search)
a large » _ large (Expand Search)
-
41
-
42
-
43
-
44
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
45
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
46
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
59
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
60